/

2142.HK

HBM HOLDINGS-BClosed

10.20−0.19 −1.83%HKD

HKSE · as of Oct 14, 04:08 ET · 15m delay

Open

10.56

Prev close

10.39

Day range

10.0710.89

52-week range

9.4617.07

Volume

11.50M1.37×

Mkt cap

8.43B

P/E ttm

11.86

Fwd P/E

12.93

EPS ttm

0.8600

Div yield

0.00%

Earnings

—

From 52w high

−40.25%

Price Chart

Yahoo Finance · delayed

2142.HKOct 14, 2026O 10.56H 10.89L 10.07C 10.20−0.19 (−1.83%)Vol 11.50M

SMA 5014.05
SMA 20012.69

1Y change −23.60% since Oct 13, 2025 close529 bars loadedTimes in Asia/Hong_KongDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

2142.HK HBM HOLDINGS-B · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −20.44%
1 month: −23.77%
3 months: −16.73%
6 months: −29.56%
Year to date: −16.39%
1 year: −21.54%

Valuation & ownership

Market cap: 8.43B
Enterprise value: 8.31B
P/E (ttm): 11.86
Forward P/E: 12.93
PEG ratio: —
Price / book: 2.57
Price / sales (ttm): 47.06
EV / EBITDA: 102.51
EPS (ttm): 0.8600
EPS (forward): 0.7887
Beta (5y monthly): 1.36
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 826.52M
Float: 527.77M
Short % of float: —
Short ratio (days): —
Held by insiders: 16.11%
Held by institutions: 22.24%
Avg volume (3m): 8.37M
50-day average: 14.09
200-day average: 12.71
52-week change: −21.54%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): oversold 28.2
vs 50-day SMA: −27.39%
vs 200-day SMA: −19.64%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 9.42%
Realised vol (20d, ann.): 76.5%
From 52-week high: −40.25%
From 52-week low: +7.82%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

20.02

+96.28% implied

Low 20.02Median 20.02High 20.02

Recommendation trend

Now2 / 0 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →trailing twelve months

DES

About HBM HOLDINGS-B

Yahoo Finance profile

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for treating myasthenia gravis; Porustobart HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4 for treating melanoma, colorectal cancer, hepatocellular carcinoma, and neuroendocrine neoplasm. It is developing HBM7020 for treating hepatocellular carcinoma and autoimmune diseases; HBM9378 for the treatment of asthma and chronic obstructive pulmonary disease; and HBM1020, HBM7022, HBM7008, HBM9027, HBM7004, and HBM9033 for treating solid tumors. The company has a strategic collaboration with Evinova to apply AI and digital technologies to enhance the efficiency of biologics development. The company was incorporated in 2016 and is based in Suzhou, the People's Republic of China.

Sector: Healthcare
Industry: Biotechnology
Employees: 327
Headquarters: Suzhou, China
Website: harbourbiomed.com
Officers: Dr. Jingsong Wang M.D., Ph.D. Founder, Chairman & CEO
Dr. C. Adam Zong MBA, Ph.D.

SEAS

Seasonality · 2142.HK

2020–2026 · monthly returns

Strongest month Dec +26.98%Weakest month Oct −18.07%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-2.5	2.1	7.8	-0.7	-10.1	-10.7	16.7	15.9	-1.8	-26.4			−16.4%
2025	94.1	42.5	73.1	-4.4	3.8	-5.0	10.8	56.6	6.6	-14.1	0.1	-9.5	+548.9%
2024	-17.5	-1.9	-12.1	-14.5	23.7	-5.5	0.0	-13.8	21.0	-16.0	-3.3	60.7	−3.1%
2023	16.0	-21.8	-17.6	-1.9	-17.5	-13.5	29.3	-11.1	-13.6	-3.4	16.3	18.3	−31.0%
2022	-29.5	-17.1	-20.9	15.2	-6.8	6.5	-19.2	-7.0	-38.9	-51.9	72.2	81.3	−63.5%
2021	-14.5	-3.4	0.7	12.3	17.0	-15.5	-5.8	-22.0	-8.0	-4.9	43.6	-15.8	−28.2%
2020													—

INSD

Insider Activity · 2142.HK

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 21, 2026	Kamen (Robert Irwin)Independent Non-Executive Director	—	81.7K	—
Apr 17, 2025	Rong (Yiping)Director (Executive)	—	131.5K	—
Apr 17, 2025	Wang (Jingsong)Chief Executive Officer	—	393K	—
Mar 30, 2025	Rong (Yiping)Director (Executive)	—	36.3K	—
Mar 30, 2025	Wang (Jingsong)Chief Executive Officer	—	281.8K	—
Jan 26, 2025	Wang (Jingsong)Chief Executive Officer	Acquisition at price 0.45 per share.	400K	$179.96K

2142.HK

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

2142.HK

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About HBM HOLDINGS-B

Seasonality · 2142.HK

Insider Activity · 2142.HK

Congress Trades · 2142.HK

Investors Holding 2142.HK

Investors Holding 2142.HK

Congress Trades · 2142.HK

Seasonality · 2142.HK

Insider Activity · 2142.HK

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About HBM HOLDINGS-B

Earnings & Dividends

News